Plain-English translation of NCT06256627 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a combination of three medications — interferon-alpha-1b, interleukin-2, and thalidomide — along with two other drugs (venetoclax and azacitidine) can help prevent acute myeloid leukemia from coming back after it has gone into remission. The study focuses on patients who have completed standard chemotherapy and either have no measurable disease remaining or still have very small amounts of disease that need to be eliminated.
Even when leukemia appears to be gone after chemotherapy, it can sometimes return. This trial exists to see whether continuing treatment with these medications after remission can reduce the chance of relapse and help patients stay in remission longer.
You likely qualify if…
You likely don't qualify if…
Participants in this trial will receive medications to take at home after completing their initial chemotherapy and achieving remission. Some patients will receive a combination of three medications, while others will receive two different medications, alternating between them over time. The study will monitor how well these treatments work at keeping the leukemia from returning and will involve regular blood tests and clinic visits to check your health and disease status.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China